Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Cancer therapy
Prognostic biomarker
Serum soluble CD26/dipeptidyl peptidase 4
YS110
Journal
Biomarker research
ISSN: 2050-7771
Titre abrégé: Biomark Res
Pays: England
ID NLM: 101607860
Informations de publication
Date de publication:
23 Mar 2021
23 Mar 2021
Historique:
received:
09
12
2020
accepted:
10
03
2021
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
25
3
2021
Statut:
epublish
Résumé
The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data. Box and Whisker plot analysis, Scatter plot analysis, Peason product moment correlation/Spearman's rank-difference correlation, Bar graph analysis, and Receiver Operating Characteristics (ROC) were used to examine the correlation between sCD26 titer variation with YS110 administration and tumor volume change, RECIST criteria evaluation and progression free survival (PFS). Mechanism for serum sCD26 titer variation was confirmed by in vitro experimentation. Serum sCD26/DPP4 titer was reduced following YS110 administration and gradually recovered until the next infusion. Serum sCD26/DPP4 titer before the next infusion was sustained at lower levels in Stable Disease (SD) cases compared to Progressive Disease cases. ROC analysis defined the cut-off level of serum sCD26/DPP4 titer variation at day 29 pre/post for the clinical outcome of SD as tumor response or PFS. In vitro experimentation confirmed that YS110 addition reduced sCD26 production from CD26-expressing tumor and non-tumor cells. Our study indicates that serum sCD26/DPP4 titer variation in the early phase of YS110 treatment is a predictive biomarker for evaluating therapeutic efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
The phase I trial of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors was conducted recently. The present study identifies a potential prognostic biomarker for CD26-targeted therapy based on the phase I data.
METHODS
METHODS
Box and Whisker plot analysis, Scatter plot analysis, Peason product moment correlation/Spearman's rank-difference correlation, Bar graph analysis, and Receiver Operating Characteristics (ROC) were used to examine the correlation between sCD26 titer variation with YS110 administration and tumor volume change, RECIST criteria evaluation and progression free survival (PFS). Mechanism for serum sCD26 titer variation was confirmed by in vitro experimentation.
RESULTS
RESULTS
Serum sCD26/DPP4 titer was reduced following YS110 administration and gradually recovered until the next infusion. Serum sCD26/DPP4 titer before the next infusion was sustained at lower levels in Stable Disease (SD) cases compared to Progressive Disease cases. ROC analysis defined the cut-off level of serum sCD26/DPP4 titer variation at day 29 pre/post for the clinical outcome of SD as tumor response or PFS. In vitro experimentation confirmed that YS110 addition reduced sCD26 production from CD26-expressing tumor and non-tumor cells.
CONCLUSIONS
CONCLUSIONS
Our study indicates that serum sCD26/DPP4 titer variation in the early phase of YS110 treatment is a predictive biomarker for evaluating therapeutic efficacy.
Identifiants
pubmed: 33757558
doi: 10.1186/s40364-021-00273-0
pii: 10.1186/s40364-021-00273-0
pmc: PMC7989014
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP20H03471
Organisme : Japan Society for the Promotion of Science
ID : JP18H02782
Organisme : Japan Society for the Promotion of Science
ID : JP20K07683
Organisme : Ministry of Health, Labour and Welfare
ID : 180101-01
Références
Clin Cancer Res. 2007 Jul 15;13(14):4191-200
pubmed: 17634548
Oncotarget. 2017 Jan 10;8(2):2995-3008
pubmed: 27936466
Clin Cancer Res. 2001 Jul;7(7):2031-40
pubmed: 11448921
Br J Cancer. 2014 Apr 29;110(9):2232-45
pubmed: 24743707
Nat Immunol. 2015 Aug;16(8):850-8
pubmed: 26075911
Sci Rep. 2014 Feb 06;4:3999
pubmed: 24499783
Nat Immunol. 2015 Aug;16(8):791-2
pubmed: 26194276
Exp Oncol. 2018 Dec;40(4):299-302
pubmed: 30593752
PLoS One. 2013 Apr 29;8(4):e62304
pubmed: 23638030
J Clin Lab Anal. 2015 Mar;29(2):106-11
pubmed: 24687574
Trends Immunol. 2008 Jun;29(6):295-301
pubmed: 18456553
BMC Cancer. 2015 Oct 15;15:703
pubmed: 26471376
Blood Cancer J. 2018 Oct 22;8(11):99
pubmed: 30348967
Biochem Biophys Res Commun. 2012 Mar 16;419(3):529-36
pubmed: 22369943
Cancers (Basel). 2019 Aug 08;11(8):
pubmed: 31398954
Dis Markers. 2020 Jan 21;2020:4347936
pubmed: 32051696
PLoS One. 2015 Mar 19;10(3):e0119436
pubmed: 25790122
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3470-7
pubmed: 16740772
Front Biosci (Landmark Ed). 2018 Jun 1;23:1754-1779
pubmed: 29772527
Diagn Pathol. 2014 Feb 06;9:30
pubmed: 24502396
Br J Cancer. 2017 Apr 25;116(9):1126-1134
pubmed: 28291776
Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14186-91
pubmed: 15353589
J Biochem. 1998 Aug;124(2):428-33
pubmed: 9685737
Mol Clin Oncol. 2019 Jan;10(1):118-124
pubmed: 30655986
Cancer Cell Int. 2016 Apr 30;16:35
pubmed: 27134571
Nat Immunol. 2019 Mar;20(3):257-264
pubmed: 30778250
Pharmacol Ther. 2019 Jun;198:135-159
pubmed: 30822465
PLoS One. 2014 Sep 11;9(9):e107470
pubmed: 25210927
Mol Immunol. 1998 Jan;35(1):13-21
pubmed: 9683260